| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78941ed5a01bfbcd48376e1fdb485b19 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N2005-1098 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-208
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-193
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 |
| filingDate |
2011-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03a11c6ee9b6a2ce2b4b815825f6748f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d5bb442377642f17977759b68be4b3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb70427a6f8cc9dcbcd021e76de349e0 |
| publicationDate |
2011-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011206635-A1 |
| titleOfInvention |
Uses of il-12 in hematopoiesis |
| abstract |
Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hernatopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of IL-12 for bone marrow preservation or recovery. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014160318-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9616106-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014178335-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9636381-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013016634-A1 |
| priorityDate |
2003-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |